MULTIPLE MYELOMA

The addition of the CELMoD mezigdomide to carfilzomib and dexamethasone led to progression-free survival improvement in relapsed/refractory multiple myeloma.

During a live event, Joshua Richter, MD, explored proactive adverse event management when using selinexor in multiple myeloma.

The FDA granted approval of the combination of teclistamab and daratumumab for patients with 1-3 prior lines of therapy in myeloma.

During a live event, Shaji Kumar, MD, discussed when talquetamab can be sequenced in multiple myeloma as an alternative to targeting BCMA in consecutive lines.

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for FDA approvals in multiple myeloma.

During a live event, Joshua Richter, MD, discussed dosing strategies when using selinexor in relapsed/refractory multiple myeloma.

The first patient was treated in a study of continuous subcutaneous administration of lenalidomide in multiple myeloma.

BCMA bispecific teclistamab delivers 63% responses and durable remissions in heavily pretreated myeloma, with new infection prophylaxis insights.

Preclinical and early clinical data showed that a proteasome inhibitor could increase BCMA expression after failure of CAR T-cell therapy.

An overview of the FDA’s draft guidance on MRD as a clinical trial end point, with expert insight on what it means for drug development in multiple myeloma.

During a live event, Marc J. Braunstein, MD, PhD, and participants discussed how recent trial findings are affecting their treatment of newly diagnosed multiple myeloma.

The FDA accepted the new drug application for iberdomide based on minimal residual disease negativity benefit shown in the EXCALIBER-RRMM trial.

In an interview, Saad Z. Usmani, MD, MBA, discussed the significance of phase 1 outcomes of gintemetostat therapy for patients with heavily pretreated multiple myeloma.

At 33.6 months' follow-up, patients with standard-risk multiple myeloma had improved progression-free survival outcomes with ciltacabtagene autoleucel vs standard of care.

A real-world ciltacabtagene autoleucel (cilta-cel) study revealed a link between high lymphocyte peaks and failed bridging to parkinsonism and nonrelapse mortality, potentially guiding early intervention.

The FDA granted fast track designation to a GPRC5D bispecific T-cell engager for multiple myeloma following positive safety and response outcomes in a dose escalation trial.

Roberto Mina, MD, discusses the distinguishing factors of the MajesTEC-3 and MajesTEC-9 trials of teclistamab in multiple myeloma.

FDA approves D-VRd, a groundbreaking treatment for newly diagnosed multiple myeloma patients ineligible for stem cell transplant, enhancing survival rates.

The FDA awarded fast track designation to a trispecific antibody targeting BCMA, GPRC5D, and CD3 in multiple myeloma.

Roberto Mina, MD, associate professor of hematology at the Winship Cancer Institute at Emory University, discussed the significance of the patient population of the MajesTEC-9 trial in patients with relapsed/refractory multiple myeloma.

The FDA released draft guidance on minimal residual disease and complete response as trial end points to accelerate multiple myeloma drug approvals.

Nivolumab after CAR T-cell therapy failure produced responses in only a small percentage of patients with myeloma or non-Hodgkin lymphoma, although responses in myeloma appeared durable.

In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas for multiple myeloma and what will come next now that this data set has been made available.

Roberto Mina, MD, discussed the significance of the early outcomes that were reported from the MajesTEC-9 trial in patients with relapsed/refractory multiple myeloma.

Topline results from the MajesTEC-9 study showed superior progression-free survival and overall survival for teclistamab in patients with 1 to 3 prior lines of treatment for multiple myeloma.